Prolongation of QT/QTc interval during medical treatment can occur not only with cardiovascular drugs but also with non-cardiovascular drugs. It may result in ventricular tachyarrhythmia, a high-risk condition which may trigger sudden cardiac death. Thus, to avoid drug-induced long QT syndrome and serious complications careful attention should be paid in the clinical setting.
Introduction
Drug-induced prolongation of QT interval has recently received intensive attention in the clinical setting, because it may be followed by the appearance of torsade de pointes-type ventricular arrhythmias (Tdp), sometimes resulting in sudden cardiac death. [1] [2] [3] It is thought that the most likely candidate for the mechanism responsible for the prolongation of the QT interval is a suppression of the IKr current through the K channel (h-ERG channel) of myocardial cell, resulting in the prolongation of the action potential duration of ventricular myocytes. An excess prolongation of action potential may sometimes cause triggered activity due to early afterdepolarization at phase 3 of the action potential that is thought to be a trigger of Tdp.
Class III antiarrhythmic drugs including sotalol, nifekalant, dofetilide and amiodarone exhibit a potent blocking action on IKr as their principal pharmacological effects, and may exert significant QT/QTc prolongation in the course of routine treatment with the drugs. Because these effects are well known and are expected beforehand, QT/QTc prolongation should be checked and managed throughout the therapy. However, not only these class III drugs but many other drugs that are used for non-cardiac purposes are also known to the latent effect of prolonging the QT interval. Besides, we know that many non-pharmacological factors surrounding the patients may have an influence on electrocardiographic parameters including the QT interval. Are drugs always entirely responsible for QT prolongation during medical therapy? Do we have a definite answer to this question?
Definition of Drug-Induced Long QT Syndrome
When we observe excess QT/QTc prolongation during a certain medical therapy, drug-induced long QT syndrome should be highly suspected, even with non-cardiac drugs. 4) In strict terms, drug-induced long QT syndrome is defined as QT/QTc interval prolongation greater than the normal range due to direct pharmacological action to the myocardial cell. However, it may be difficult to definitely differentiate QT/QTc prolongation associated with a direct effect of the drug on the myocardium from the effect of the drug on other tissues or organs with no effect on myocardial cells. For example, we sometimes find that the QT/QTc interval has been prolonged by loop diuretic agents associated with lowering the serum [K+] level. Also, we may not be able to differentiate the effect on QT/QTc prolongation of various acquired factors including bradycardia, myocardial ischemia, cerebrovascular diseases, and electrolyte imbalance, as listed in Table 1 , from that of drugs only.
We must assume that there are no drugs which never prolong the QT/QTc interval under any conditions and that all patients who are taking any kind of drugs have a risk for QT/QTc prolongation. However, in the real world, it is not appropriate to check ECG at every hospital visit in all patients. Practically, it is important to know which types of drugs have the potential to prolong QT/QTc interval due to their K channel blocking action under usual clinical dosage. Table 2 is a list of drugs other than class III antiarrhythmic agents with the potential for prolongation of QT/QTc interval as reported in the literature. 5, 6) Not only drugs for cardiovascular diseases including Na channel blocking agents and antianginal drugs, but also many other drugs for noncardiovascular use such as neuroleptics, antidepressants, antihistamines, antibiotics, and antineoplastics are listed. We have to be very careful to see that the list is never complete. It is thought that many drugs not on this list might prolong QT/QTc interval. This list should be considered the ''tip of an iceberg.''
Problems of QT/QTc Prolongation due to Non-Cardiovascular Drugs
It is sometimes very difficult to check QT/QTc interval in the daily clinical practices especially during non-cardiovascular drug therapy. There are many problems in the management of QT/QTc interval because the targets of the treatment are not cardiovascular diseases. Related problems are listed in Table 3 . Usually non-cardiovascular drugs are prescribed by physicians who are not cardiology specialists. These physicians will not attempt to record ECGs before and after the prescription except in the specific patients who have underlying cardiovascular diseases, because they may not be familiar with the clinical importance of QT/QTc prolongation induced by non-cardiovascular drugs.
Since automatic measurement of QT/QTc by the built-in computers of ECG systems is sometimes inaccurate, especially under noisy conditions, a physician with sufficient experience and knowledge in accurately reading ECGs may be requested for the appropriate evaluation of QT/QTc prolongation. 7, 8) It is not easy to monitor QT/QTc intervals thoroughly throughout a drug therapy. A certain drug that has little effect on QT/QTc interval prolongation during the administration of a single drug may exert significant prolongation suddenly with an unexpected elevation of the serum concentration due to drug interaction when another drug is prescribed concomitantly. Table 3 Problems in evaluation of QT interval under non-cardiovascular drug therapy.
1.
Treatment target is not cardiovascular disease.
2.
Attending doctor is not a cardiology specialist.
3.
ECG will not be record before prescription of the drug. 4.
ECG will not be record even after prescription of the drug.
5.
Attending doctor may not be familiar with QT/QTc prolongation. 6.
Accuracy of automatic measurement of QT interval is not always enough. 7.
QT/QTc prolongation is sometimes concealed and may appear suddenly. 8.
Unexpected prolongation may occur due to pharmacological interaction.
Measurement of QT Interval
Recently, ICH-E14 reached step 5 agreement and has requested that millisecond-level variation of QT interval should be precisely detected using an authorized method during clinical trials for all new drugs even if they have little or no cardiovascular effect (thorough QT/QTc study). [9] [10] [11] Thus, the construction of an objective QT measurement system with high quality and performance is urgently needed to meet the request of ICH (cf. http:// www.ich.org). Table 4 shows various methods that measure QT interval in the clinical setting. [12] [13] [14] [15] [16] [17] [18] [19] An automatic measurement using the built-in computer of ECG machines will be the easiest way to measure a large quantity of ECGs. However, the ICH does not recommend it because of the questionable reliability of the data. ICH requests a manual over-read system to check the measured data by an authorized cardiology specialist, especially in the early phase of study for new drug development. 20) Several secondary analyses applying certain mathematical approaches are expected as shown in Table 4 . We are studying the possibility of using the wavelet transform analysis for the measurement of QT interval. 21) Since the wavelet analysis has a time-and frequency-domain nature, time-relevant information might be preserved even during frequency analysis. 22, 23) We believe that the method will be applicable for the accurate measurement of QT interval in cases of flat or inverted T wave as illustrated in Figure 1 , but whether or not the method will be used is still under consideration.
Determination of the Terminal Point of T Wave
In the clinical setting, it is sometimes difficult to determine the real point of termination of the T wave on the ECG not only due to noise, drift, and artifacts Katoh T Drug-Induced Long QT Syndrome but also due to flattened or biphasic T waves or a prominent U wave, depending upon the underlying disease. 24) It is very difficult to measure QT intervals in every beat with a high grade of accuracy. 25) There are many options as to the methods for determining the terminal point of the T wave from the ECG recordings. Among them the tangent method and the threshold method are widely used. It is known that the tangent method is slightly superior in reproducibility of measurement and has less inter-observer variation than the threshold method. However, in case of biphasic or bizarre T wave or severe baseline drift, a tangent line at the down slope of the T wave sometimes cannot be drawn appropriately. The threshold method can be applied even in those cases. It is thought that in the real world QT intervals are measured using both methods on a case-by-case basis. It is better, however, that these methods are not mixed during the drug study if at all possible. A second method should be used only to make corrections in case of significant discrepancies in the value of QT interval measurement.
Before starting QT interval measurement, it is essential to reach an agreement on the basic of method where to draw the baseline and the tangent line as illustrated in Figure 2 .
Correction of Measured QT Interval (QTc)
QT intervals may fluctuate frequently and instantaneously due to the change of various physiological or pathological factors of the patients. Change of heart rate is the main factor that may influence QT interval. Many methods have been developed to correct the QT interval for heart rate. [26] [27] [28] [29] [30] [31] [32] The measured QT intervals should be corrected by the heart rate using several correction formulae as shown in Table 5 . Bazett's formula (QTc = QT/RR 1=2 ) is most widely used. It is simple and easily applicable, Over the signal or under the signal?
Baseline was PP or QQ?
Terminal point of T wave? Baseline in case of severe drift? Figure 2 How to draw the baseline and the tangent line on the electrocardiogram. Compare QT at HR 60-70/min before and after drug administration but the formula is aimed to adjust the QT interval during a heart rate around 60 beats per minute. However, Bazett's formula becomes less accurate, underestimating repolarization duration at slow heart rates and overestimating at fast heart rates. It may not be suitable for studies involving drugs that may bring a great change of the heart rate. Fridericia's formula (QTc = QT/RR 1=3 ) is also available. Compared to Bazett' formula, the overestimation at faster heart rates is thought to be less and it is used most frequently in the drug approval process. However, the calculation process is more complicated. Several new methods for correction of QT interval using linear regression analysis have been recently applied. If sufficient data of successive QT and RR intervals are available to get the QT/RR relationship before and after the study, QTcI might be the most reliable correction method in individual patients. Another approach to deal with QT interval is the so-called RR bin method. When the stable Holter ECG before and after the drug administration have been recorded, absolute QT intervals at similar heart rates can simply be compared without mathematical heart rate corrections.
Thorough QT/QTc Study
According to the recently-issued ICH E-14 statement, a ''thorough QT/QTc study'' is intended to determine whether the drug has a threshold pharmacologic effect on cardiac repolarization, as detected by QT/QTc prolongation. 10, 11) The threshold level of regulatory concern is around 5 msec as evidenced by an upper boundary of the 95% confidence interval around the mean effect on QTc of 10 msec. The study is typically carried out in healthy volunteers and is used to determine whether or not the effect of a drug on the QT/QTc interval in target patient populations should be studied intensively during later stages of drug development including phase II and phase III clinical studies. It is not intended to identify drugs as being pro-arrhythmic. The results of the ''thorough QT/QTc study'' is not expected to be affected by ethnic factors.
Planning of the Clinical Trials in the Development of New Drugs
Regardless of whether the drug is a cardiac or non-cardiac agent, drug companies are requested to perform an adequate pre-marketing investigation to demonstrate safety, including detailed characterization of the drug's effects on the QT/QTc interval in humans.
ICH has recommended a rule in the clinical evaluation of risk for QT/QTc prolongation in its E14 documents. The recommendations contained in this document are generally applicable to new drugs having systemic bioavailability, but may not apply to products with highly localized distribution and those administered topically and not absorbed. Antiarrhythmic drugs known to prolong the QT/QTc interval are excluded from this concept. Although E14 is primarily concerned with the development of new drugs, the recommendations might also be applicable to approved drugs when a higher dose or a new route of administration results in significantly higher exposure. Besides, the evaluation of QT interval would also be considered important if the drugs with similar pharmacological action have been associated with QT/QTc interval prolongation, TdP, or sudden cardiac death during post-marketing surveillance.
Conclusion
I have raised the question at the beginning of this review whether drugs are always fully responsible for QT prolongation during medical therapy. Unfortunately, we have no definite answer to that question. Because various non-pharmacological factors other than drugs used may have an influence on the QT/QTc interval, we must be very careful in evaluating ECG data during the clinical study of new drugs. It is essential to plan studies elaborately in a highly individualized manner taking into consideration the characteristics of each drug.
